Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5555-5564

  Wu, Huali ^a   Ramanathan, Ramesh K ^b   Zamboni, Beth A ^c   Strychor, Sandra ^d   Ramalingam, Suresh ^e   Edwards, Robert P ^d   Friedland, David M ^d   Stoller, Ronald G ^d   Belani, Chandra P ^d   Maruca, Lauren J ^d   Bang, Yung Jue ^f   Zamboni, William C ^a,g  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c CARLOW UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f Seoul National University   (South Korea)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Nonlinear kinetics; PEGylated liposome; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

BELOTECAN; LIPOSOME; MACROGOL; S CKD 602; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CELL COUNT; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG MECHANISM; ENCAPSULATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MATHEMATICAL MODEL; MOLECULAR INTERACTION; MONOCYTE; MONOCYTOPENIA; PHARMACODYNAMICS; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COMPUTER SIMULATION; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONOCYTES; NEOPLASMS; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS;

EID: 84870352919     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S35751     Document Type: Article

References (41)

1. Zamboni WC, Strychor S, Joseph E, etal. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602in mice bearing A375 human melanoma xenografts. Clin Cancer Res. 2007;13(23):7217-7223.
2. Zamboni WC, Eiseman JL, Strychor S, etal. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. J Liposome Res. 2011;21(1):70-80.
3. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res. 2005;11(23):8230-8234.
4. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs. 2003; 4(12):1455-1459.
5. Lee JH, Lee JM, Lim KH, etal. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci. 2000; 922:324-325.
6. Lee DH, Kim SW, Suh C, etal. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol. 2008;19(1):123-127.
7. Yu NY, Conway C, Pena RL, Chen JY. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res. 2007;27(4B):2541-2545.
8. Zamboni WC, Friedland DM, Ramalingam S, etal. Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24(Suppl 18):S2013.
9. Slatter JG, Schaaf LJ, Sams JP, etal. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11in cancer patients. Drug Metab Dispos. 2000;28(4): 423-433.
10. Zamboni WC, Stewart CF, Thompson J, etal. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst. 1998;90(7):505-511.
11. Stewart CF, Zamboni WC, Crom WR, etal. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs. 1996;14(1):37-47.
12. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13(3):248-260.
13. Innocenti F, Kroetz DL, Schuetz E, etal. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604-2614.
14. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2): 133-141.
15. Papahadjopoulos D, Allen TM, Gabizon A, etal. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460-11464.
16. Zamboni WC, Maruca LJ, Strychor S, etal. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res. 2011;21(2):158-165.
17. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
18. Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol. 1999;22(1):103-105.
19. Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer. Am J Clin Oncol. 2000;23(3): 278-282.
20. Friberg LE, Freijs A, Sandström M, Karlsson MO. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther. 2000;295(2): 734-740.
21. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713-4721.
22. Minami H, Sasaki Y, Saijo N, etal. Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther. 1998;64(5):511-521.
23. Krzyzanski W, Jusko WJ. Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn. 2002;29(4):311-337.
24. Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol. 2008;62(1):123-133.
25. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481-5490.
26. Léger F, Loos WJ, Bugat R, etal. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther. 2004;76(6):567-578.
27. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):412-426.
28. Fetterly GJ, Grasela TH, Sherman JW, etal. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008;14(18):5856-5863.
29. van Kesteren C, Zandvliet AS, Karlsson MO, etal. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs. 2005;23(3):225-234.
30. Zamboni WC, Ramalingam S, Friedland DM, etal. Phase I and pharmacokinetic study of pegylated liposomal CKD-602in patients with advanced malignancies. Clin Cancer Res. 2009;15(4):1466-1472.
31. Zamboni WC, Strychor S, Maruca L, etal. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther. 2009;86(5):519-526.
32. McKenzie SB. Clinical Laboratory Hematology. 2nd ed. Upper Saddle River, NJ: Prentice Hall; 2010.
33. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 1st ed. New York, NY: Springer Science and Business Media, Inc; 2005.
34. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6): 553-571.
35. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5(5):445-479.
36. Hilger RA, Richly H, Grubert M, etal. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther. 2005;43(12): 588-589.
37. Jain NC. Essentials of Veterinary Hematology. 1st ed. Hoboken, NJ: John Wiley and Sons; 1993.
38. Whitelaw DM. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet. 1972;5(4):311-317.
39. Koning GA, Morselt HW, Kamps JA, Scherphof GL. Uptake and intracellular processing of PEG-liposomes and PEG-immunoliposomes by kupffer cells in vitro 1*. J Liposome Res. 2001;11(2-3):195-209.
40. Van Rooijen N, Sanders A. Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology. 1996;23(5):1239-1243.
41. Haber E, Afergan E, Epstein H, etal. Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J Control Release. 2010;148(2):226-233.